Dataset-22264682 Search Result

Clinical Information

Characteristics of 23 children in whom clinically significant respiratory syncytial virus respiratory tract infection developed while receiving palivizumab immunoprophylaxis, Canada, 2006–2010*

Location and patient ID

Age, mo/ sex†

GA at birth, wk + d

Underlying comorbidities

No. doses PZB‡

Delay, d§

Clinical diagnoses

H

Multiplex PCR/DNA results

Mutation

Québec City, Québec (2006–2010)

C0607-1023

9/F

32 + 4

Prematurity, LBW

3

21

Bronchiolitis

No

RSV-A;enterovirus type A

K272Q

H0607-064

24/M

38 + 3

Congenital myopathy

3

15

Pneumonia;bronchospasm

Yes

RSV-B

NF

H0607-132

12/M

38 + 5

Pulmonary artery stenosis

5

7

Bronchiolitis

Yes

RSV-A

NF

H0708-199

4/M

30 + 4

Prematurity, VLBW

4

14

Bronchiolitis

Yes

RSV-B

NF

H0809-037

11/F

27 + 5

Prematurity, ELBW

3

14

Bronchiolitis

Yes

RSV-A

NF

C0809-1055

6/F

29 + 0

Prematurity, ELBW, triplet

4

27

Bronchiolitis

No

RSV-A

N276S

C0809-1056

6/M

29 + 0

Prematurity, ELBW, triplet

4

27

Bronchiolitis

No

RSV-A

N276S

C0809-1057

6/M

29 + 0

Prematurity, VLBW, triplet

4

27

Bronchiolitis

No

RSV-A

N276S

H0910-004

4/F

39 + 5

Choanal hypoplasia

1

16

Apnea;upper RTI

Yes

RSV-A

N276S

H0910-140

6/M

25 + 5

Prematurity, ELBW

4

29

Bronchiolitis

Yes

RSV-B

NF

H0910-144

13/F

26 + 5

Prematurity, VLBW

4

7

Pneumonia

Yes

RSV-A

K272M, N276S

H0910-150

9/M

28 + 3

Prematurity, VLBW

4

12

Upper RTI;acute otitis media

Yes

RSV-A;adenovirus type C

N276S

Montréal, Québec (2009–2010)

MCH0910-001

15/M

40 + 4

Total anomalous pulmonary venous return

3

26

Pneumonia

Yes

RSV¶

N276S

MCH0910-002

6/F

39 + 0

Pulmonary valve stenosis, right aortic arch

2

7

Bronchiolitis

Yes

RSV¶

N276S

MCH0910-003

5/M

39 + 6

Cystic fibrosis

3

24

Bronchiolitis

No

RSV¶

N276S

MCH0910-004

7/M

36 + 2

Prematurity, BPD hypotonia

4

6

Bronchiolitis

Yes

RSV¶

N276S

MCH0910-005

15/M

40 + 4

Neuromuscular disorder, recurrent aspirations

4

13

Upper RTI;acute otitis media

No

RSV¶

N276S

MCH0910-006

2/M

34 + 6

Prematurity, LBW

1

14

Bronchiolitis

Yes

RSV¶

N276S

MCH0910-007

19/F

25 + 0

Prematurity, ELBW, BPD

3

19

Bronchiolitis, bronchospasm

Yes

RSV¶

N276S

MCH0910-008

2/F

38 + 1

Neuromuscular disorder, ventricular septal defect

2

12

Bronchiolitis

Yes

RSV¶

N276S

Hamilton, Ontario (2009–2010)

MAC0910-001

1/F

34 + 5

Prematurity, LBW

2

3

Bronchiolitis

Yes

RSV¶

N276S

MAC0910-002

6/F

34 + 3

Prematurity, LBW, twin

1

25

Bronchiolitis

Yes

RSV¶

N276S

MAC0910-003

6/F

34 + 3

Prematurity,VLBW, IUGR, twin

1

27

Bronchiolitis

Yes

RSV¶

N276S

*Patient identification (ID) nomenclature: hospitalized (H) or clinic (C) prospective study participant, Montréal Children’s Hospital (MCH) or McMaster Children’s Hospital (MAC) patient. GA, gestational age; PZB, palivizumab; multiplex PCR/DNA, hybridization assay; mutation, mutation in respiratory syncytial virus fusion protein PZB binding site (residues 262–276); RSV, respiratory syncytial virus; LBW, low birthweight (1,500–2,500 g); NF, no mutation found in PZB binding site; VLBW, very low birthweight (1,000–1,499 g); ELBW, extremely low birthweight (<1,000 g); RTI, respiratory tract infection; BPD, bronchopulmonary dysplasia; IUGR, intrauterine growth restriction.

†Median patient age 6.0 mo (range 1–24 mo).

‡Mean ± SD no. palivizumab doses received that winter: 3.0 ± 1.2 doses.

§Median interval between last palivizumab dose and symptom onset: 15.0 d (range 3–27 d).

¶Retrospectively identified participants from Montréal Children’s Hospital or McMaster Children’s Hospital were RSV-positive by direct immunofluorescence assay (Chemicon International, Temecula, CA, USA) and were not tested by the multiplex PCR/DNA hybridization assay (14).